This is a summary of the European public assessment report (EPAR) for Vizarsin. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vizarsin.
Therapeutic Indication
### Therapeutic indication Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Vizarsin to be effective, sexual stimulation is required.
Therapeutic Area (MeSH)
N/AATC Code
G04BE03
ATC Item
sildenafil
Pharmacotherapeutic Group
Urologicals
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| sildenafil | N/A | 西地那非 |
EMA Name
Vizarsin
Medicine Name
Vizarsin
Aliases
N/ANo risk management plan link.
